Tech Company Financing Transactions
XyloCor Therapeutics Funding Round
XyloCor Therapeutics secured a $17 million Series A funding round on 12/7/2018. Backers included Life Sciences Partners, Sofinnova Ventures and private investors.
Transaction Overview
Company Name
Announced On
12/7/2018
Transaction Type
Venture Equity
Amount
$17,000,000
Round
Series A
Investors
Life Sciences Partners (Lead Investor)
Sofinnova Ventures (Lead Investor)
Proceeds Purpose
Proceeds from the financing will be used to advance the development of lead product candidate XC001, a cardiovascular angiogenic gene therapy, and expand the company's business and operational structure.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
76 Longview Ln.
Newtown Square, PA 19073
USA
Newtown Square, PA 19073
USA
Phone
Website
Email Address
Overview
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. Our lead product candidate, XC001, is in clinical development for patients with refractory angina for which there are no treatment options.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Albert Gianchetti
Chief Medical Officer
Rickey Reinhardt
VP - Finance
Michael Carson
VP - Manufacturing
Alexander Gaidamaka
VP - Operations
Dawn Byrnes
VP - R & D
Howard Dittrich
Browse more venture capital transactions:
Prev: 12/7/2018: MoEngage venture capital transaction
Next: 12/7/2018: Snapt venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs